CEO Today Middle East Awards

www.ceotodaymagazine.com 26 CEO Today Middle East Awards 2018 ISRAEL PHILIP A. SERLIN CEO of BioLineRx ABOUT PHILIP A. SERLIN Mr. Philip A. Serlin, CPA, MBA has been the Chief Executive Officer at BioLineRx, Ltd., since October 10, 2016. Mr. Serlin served as the Chief Financial and Operating Officer of BioLineRx, Ltd. from May 24, 2009 to October 10, 2016 and also served as its Principal Accounting Officer until October 10, 2016. Mr. Serlin served as the Chief Financial Officer and Chief Operating Officer of Kayote Networks, Inc from January 2008 to August 2008. He served as Vice President of Finance at TesCom Software Systems Testing Ltd. from January 2006 to December 31, 2007 and served as its Chief Financial Officer from January 2006 to December 2007. Mr. Serlin joined Tescom from Chiaro Networks Ltd., where he served as Corporate Controller and Finance Manager since 2000 and also served as its Vice President of Finance. From January 2000 to December 2005, he served as Chief Accounting Officer for Chiaro Networks Ltd. He has over 25 years of experience in accounting and finance. He has extensive experience of financial reporting and regulatory affairs. From June 1986 to December 1992, he served as senior accountant/ analyst and Technical Accounting Advisor/Investigator at the US Securities and Exchange Commission. He served in a number of senior managerial roles at leading Israeli companies. From January 1994 to December 1999, he served as Senior Manager at Deloitte Touche Tohmatsu (Brightman, Almagor & Co), where he headed the SEC and U.S. accounting department at the Tel Aviv national office. He served senior financial positions with other publicly traded companies, as well as at Deloitte and the Securities and Exchange Commission (SEC). He has been an Independent Director of Vascular Biogenics Ltd. since February 11, 2015. He served as a Director of Vringo, Inc. from May 2010 to July 19, 2012. He served as Director of Kitov Pharmaceuticals Holdings Ltd. since July 2013 until March 2016. He is a Certified Public Accountant. Mr. Serlin is a Member of the American Institute of Certified Public Accountants and holds a Master of Business Administration from the George Washington University, USA. He holds a Master’s degree in Economics and Public Policy from The George Washington University. Mr. Serlin holds a BS Degree in Accounting from Yeshiva University. FIRM PROFILE BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/ or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx’s leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and is expected to initiate a Phase 3 study in stem cell mobilization for autologous transplantation; and AGI- 134, an immunotherapy treatment in development for multiple solid tumors, which is expected to initiate a first-in-man study in the first half of 2018. www.biolinerx.com